Abstract: An enzymatic process for producing fatty acid triglycerides using a lipase catalyst system that includes a mixture of a supported lipase catalyst and an additive, such as silica gel. The additive is used without adsorbing any of the acyl group donor or acyl group acceptor reactants onto the additive. Use of the catalyst system decreases production reaction time, decreases the temperatures required for reaction, and allows for a single reaction vessel. The catalyst system can be used to efficiently produce medium chain triglycerides or conjugated linoleic acid triglycerides.

Abstract: An enzymatic process for producing fatty acid triglycerides using a lipase catalyst system that includes a mixture of a supported lipase catalyst and an additive, such as silica gel. The additive is used without adsorbing any of the acyl group donor or acyl group acceptor reactants onto the additive. Use of the catalyst system decreases production reaction time, decreases the temperatures required for reaction, and allows for a single reaction vessel. The catalyst system can be used to efficiently produce medium chain triglycerides or conjugated linoleic acid triglycerides.

Abstract: A process for preparing a conjugated linoleic acid (CLA) material that is enriched in the cis 9, trans 11 (rumenic acid) CLA isomer. The process involves subjecting a material containing at least 75 weight % CLA moieties to an enzymatic conversion, wherein the enzyme has the ability to discriminate between the cis 9, trans 11 and trans 10, cis 12 isomers. The enzyme is advantageously a lipase derived from Candida rugosa. The resulting CLA product stream is distilled to separate the free fatty acid fraction from the glyceride fraction. The recovered free fatty acid fraction contains about 55 weight % to about 70 weight % of the cis 9, trans 11 isomer (rumenic acid), and has a weight ratio of cis 9, trans 11 isomer to trans 10, cis 12 isomer of at least 3.5:1. The material enriched in rumenic acid may be used in foods, particularly infant formulas, or in food supplements or in pharmaceutical compositions.

Abstract: Micronized tanaproget, purified tanaproget Form I, and micronized, purified tanaproget Form I are provided. Also provided are compositions containing one or more of the prepared tanaproget forms, methods of using one or more of the prepared tanaproget forms, and kits containing one or more of the prepared tanaproget forms.

Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1 (PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.

Abstract: The present invention relates to processes for synthesizing piperazine-piperidine compounds, and compounds useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. The processes also allow for safer and environmentally tolerant production of these useful compounds.

Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.

Abstract: Micronized tanaproget, purified tanaproget Form I, and micronized, purified tanaproget Form I are provided. Also provided are compositions containing one or more of the prepared tanaproget forms, methods of using one or more of the prepared tanaproget forms, and kits containing one or more of the prepared tanaproget forms.

Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.

Abstract: The present invention provided an improved method for preparing a boratabenzene derivative. The invention includes an improved preparation of 1,4-pentadiyne, 1-haloboracyclohexa-2,5-diene, and 1-methylboracyclohexa-2,5-diene intermediates. These compounds are chemically labile and are not directly isolated from solution. Furthermore, the invention discloses an improved preparation of 1,1-dialkylstannacyclohexa-2,5-diene, another intermediate useful for preparing boratabenzene derivatives.

Abstract: The present invention provided an improved method for preparing a boratabenzene derivative. The invention includes an improved preparation of 1,4-pentadiyne, 1-haloboracyclohexa-2,5-diene, and 1-methylboracyclohexa-2,5-diene intermediates. These compounds are chemically labile and are not directly isolated from solution. Furthermore, the invention discloses an improved preparation of 1,1-dialkylstannacyclohexa-2,5-diene, another intermediate useful for preparing boratabenzene derivatives.